News from immune pharmaceuticals inc

Nov 26, 2013, 00:01 ET

Immune Pharmaceuticals' Common Stock Approved for Trading on NASDAQ OMX First North Premier

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that its common stock has been approved for...

Nov 20, 2013, 00:01 ET

Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) ("Immune" or the "Company") announced today its financial results...

Nov 01, 2013, 00:01 ET

Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that it has appointed Erik Penser Bankaktiebolag...

Oct 16, 2013, 00:01 ET

New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Tomer Adar, M.D. at the Digestive Diseases...

Oct 15, 2013, 00:01 ET

Immune Pharmaceuticals Announces Changes to its Board of Directors

Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP), announced today that Rene Lerer, M.D., Executive Chairman of Magellan...

Oct 03, 2013, 00:01 ET

IMMUNE Pharmaceuticals Inc. to Present at 12th Annual BIO Investor Forum

 Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Dr. Daniel G. Teper, Company Chairman and...

Sep 30, 2013, 00:01 ET

Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States

 Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange and OTCQX: IMNP) ("IMMUNE" or the "Company") announced today that following the...

Sep 23, 2013, 00:01 ET

Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform

 Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced today that effective September 23,...

Sep 04, 2013, 00:01 ET

Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013

Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) today announced it will be featured as a presenting company at...

Aug 27, 2013, 00:01 ET

Immune Pharmaceuticals Restructures Secured Loan Following Completion of Merger

 Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) ("Immune" or the "Company") announced today that it has...

Aug 26, 2013, 00:01 ET

Immune Pharmaceuticals Completes Merger with EpiCept Corporation

 Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) (the "Company") announced today the completion of the...

Apr 23, 2013, 06:00 ET

Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"

 Immune Pharmaceuticals Ltd. ("Immune"), a privately held Israeli company, announced today that the company's CEO Daniel Teper is the moderator...

Nov 29, 2011, 09:22 ET

Isaac Kobrin, M.D. Joins IMMUNE Pharmaceuticals' Board of Directors

IMMUNE Pharmaceuticals, an emerging leader in the development of antibody based therapeutics for the treatment of inflammatory diseases and cancer,...

Sep 13, 2011, 08:07 ET

IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer

IMMUNE Pharmaceuticals, an emerging leader in the development of Antibody based Therapeutics for the treatment of inflammatory diseases and cancer,...

Jun 09, 2000, 01:00 ET

The Immune Response Corporation and Agouron Pharmaceuticals, Inc. Announce ACTG Study Update

CARLSBAD, Calif. and LA JOLLA, Calif., June 9 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) and Agouron Pharmaceuticals, Inc....

May 10, 2000, 01:00 ET

The Immune Response Corporation and Agouron Announce the Initiation Of a Pivotal Clinical Trial of REMUNE(TM), an Investigational Immune-Based Therapy for the Treatment of HIV Infection

CARLSBAD, Calif., and LA JOLLA, Calif., May 10 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) and Agouron Pharmaceuticals, Inc....

May 17, 1999, 01:00 ET

Independent Panel Recommends Concluding Clinical Endpoint Trial of REMUNE; Agouron Pharmaceuticals, Inc. and The Immune Response Corporation To Pursue Alternative Regulatory Strategy

CARLSBAD, Calif. and LA JOLLA, Calif., May 17 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) and Agouron Pharmaceuticals, Inc....

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Analysts Review